Alderley Park Ventures

BioCity is a leading life sciences incubator and early-stage investor, renowned for its focus on nurturing innovative ventures within the UK’s vibrant biotech ecosystem. With hubs across Nottingham, Alderley Park, and Scotland, BioCity supports a wide array of startups, especially those pioneering breakthroughs in biotechnology, medical devices, and drug discovery. The fund typically invests between £50,000 to £250,000, targeting companies at the seed stage, often co-investing alongside industry giants like AstraZeneca and prominent angel investors. Notable investments include Maxwellia, a pioneer in converting prescription drugs to over-the-counter solutions, and NanoSyrinx, which is developing precision therapeutics. BioCity's strategic approach is sector-agnostic within life sciences, providing not just capital but also high-end laboratory space, business support, and access to a network of industry experts. The team is led by seasoned professionals, including Dr. Imelda Juniarsih, known for her keen eye in identifying high-potential early-stage ventures. While their primary geographic focus is the UK, they are open to opportunities that align with their mission of advancing life sciences innovation. Startups seeking investment are encouraged to engage early, as BioCity values deep, collaborative relationships with its portfolio companies, often built through long-term incubation and mentorship.